Study immune response in adults with psoriasis on tildrakizumab
Part of Immune system & allergy, Skin clinical trials.
This trial studies how the immune system responds in adults with moderate-to-severe psoriasis when receiving tildrakizumab. The goal is to better understand treatment effects and immune changes, which may help improve care for people with psoriasis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have moderate-to-severe psoriasis, or more than 5% of your body affected.
- You have not taken medicines that strongly suppress the immune system in the last 4 weeks.
- You are not pregnant and not breast-feeding.
- You do not have severe immune problems (from genetic causes or infections).
- You do not have active tuberculosis or another serious active infection, and no active cancer requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a proactive approach (adjusting drug levels based on regular blood tests) versus the usual way of using biologics for psoriasis. It helps see if active monitoring can improve treatment while keeping you safe.
This trial studies how the immune system changes in the skin after guselkumab treatment for psoriasis, including the scalp. You may be asked to meet certain scalp severity and medication safety rules.
This trial tests whether tildrakizumab, a biologic medicine, can help people with psoriasis that affects their genital area. It aims to see if the drug reduces symptoms like redness and scaling in those sensitive regions.
This trial is for adults with moderate to severe plaque psoriasis who are currently on a biologic treatment (like Humira, Stelara, or Cosentyx) and are switching to tildrakizumab. It looks at how your quality of life and symptoms change after the switch.
This study looks at how well tildrakizumab works for people with moderate-to-severe plaque psoriasis who are starting this treatment through a support program in Canada. Researchers want to see how it affects your symptoms and daily life.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
Hear when a new Psoriasis Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.